Physician profile
Marla Klein
NPI 1912990664
$11,490.48
in general payments reported to CMS, 2019-2025
26 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $674 · 2021: $3,099 · 2022: $1,861 · 2023: $2,258 · 2024: $1,532 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,186 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,185.50 |
| Education | $228.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,505.67 | 2019-2023 | |
| Abbvie INC. | $3,173.72 | 2019-2025 | |
| Janssen Biotech, INC. | $766.41 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $431.00 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $382.61 | 2019-2025 | Aklief, Oracea, Twyneo |
| E.R. Squibb & Sons, L.L.C. | $308.67 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $215.51 | 2019-2025 | |
| Genzyme Corporation | $198.62 | 2019-2025 | |
| Biofrontera INC. | $157.04 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $142.27 | 2020-2024 | Otezla |
| Pfizer INC. | $140.86 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $128.60 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.26 | 2019-2021 | |
| Dermavant Sciences, INC. | $114.12 | 2023-2024 | Vtama |
| Incyte Corporation | $108.29 | 2022-2025 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $96.62 | 2019-2023 | Absorica Ld, Ilumya |
| Almirall LLC | $90.10 | 2019-2020 | |
| Leo Pharma INC. | $73.93 | 2019-2025 | Anzupgo, Adbry |
| Revance Therapeutics, INC. | $65.11 | 2024-2025 | Daxxify |
| Mayne Pharma Commercial LLC | $62.18 | 2019-2021 | |
| Dermira, INC. | $61.28 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $58.77 | 2020 | |
| Celgene Corporation | $39.12 | 2019 | |
| Ucb, INC. | $21.02 | 2024 | Bimzelx |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Organon LLC | $10.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.